Article
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Blood - 6 Jun 2013
Ravandi Farhad, Alattar Mona Lisa, Grunwald Michael R, Rudek Michelle A, Rajkhowa Trivikram, Richie Mary Ann, Pierce Sherry, Daver Naval, Garcia-Manero Guillermo, Faderl Stefan, Nazha Aziz, Konopleva Marina, Borthakur Gautam, Burger Jan, Kadia Tapan, Dellasala Sara, Andreeff Michael, Cortes Jorge, Kantarjian Hagop, Levis Mark
Abstract excerpt
Patients received 5-azacytidine (AZA) 75 mg/m(2) intravenously daily for 7 days and sorafenib 400 mg orally twice daily continuously; cycles were repeated at ~1-month intervals. Forty-three acute myeloid leukemia (AML) patients with a median age of 64 years (range, 24-87 years) were enrolled; 37 were evaluable for response. FMS-like tyrosine kinase-3 (FLT3)-internal tandem duplication (ITD) mutation was detected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.